Beijing Beilu Pharmaceutical Co., Ltd. (300016.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

24.6x

Market Cap

CNY 5.67B

MomentumView details →

1D Return

−6.70%

YTD Return

+6.68%

RSI (14)

46.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

24.6x

Market Cap

CNY 5.67B

RSI (14)

46.4

MomentumView details →

1D Return

−6.70%

YTD Return

+6.68%

ProfitabilityView details →

Gross Margin

46.07%

Net Margin

9.91%

EBITDA Margin

17.04%

ROE (TTM)

5.35%

ROA (TTM)

3.58%

Asset Turnover

0.37x

GrowthView details →

Revenue YoY

+17.40%

EPS YoY

+613.22%

FCF YoY

−93.28%

Revenue CAGR 3Y

+16.32%

EPS CAGR 3Y

+108.01%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.06

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

2.39x

Quick Ratio

1.80x

Div Yield

—

Div Rate

—

Div Growth 1Y

−28.57%

Financials snapshotView financials →

Revenue (TTM)

1.24B

Net Income (TTM)

123.17M

Op. CF (TTM)

232.85M

Latest newsMore news →

Beijing Beilu Pharmaceutical's deputy general manager Zong Li completed a share reduction plan, selling 30,600 shares via centralized bidding from July 14 to August 28, 2026, at an average price of 9.05 yuan per share.6d ago

Beijing Beilu Pharmaceutical announced its H1 2026 results: revenue of 673 million yuan, up 15.26% year-on-year; net profit attributable to shareholders of 79.7521 million yuan, up 166.13% year-on-year.13d ago

Similar companies

常宝股份002478.SZ 精华制药002349.SZ 明月镜片301101.SZ 精锻科技300258.SZ 铭普光磁002902.SZ 广东鸿图002101.SZ Find similar companies →

Latest newsMore news →

Beijing Beilu Pharmaceutical's deputy general manager Zong Li completed a share reduction plan, selling 30,600 shares via centralized bidding from July 14 to August 28, 2026, at an average price of 9.05 yuan per share.6d ago Beijing Beilu Pharmaceutical announced its H1 2026 results: revenue of 673 million yuan, up 15.26% year-on-year; net profit attributable to shareholders of 79.7521 million yuan, up 166.13% year-on-year.13d ago